Table 1.
Relationship of HNRNPA2B1 expression and clinicopathologic characteristics of prostate patients
| Variables | HNRNPA2B1 expression | P value | |
|---|---|---|---|
| Low | High | ||
| N | 121 | 30 | |
| Age, year | 0.177 | ||
| < 70 | 60 (49.59%) | 19 (63.33%) | |
| ≥ 70 | 61 (50.41%) | 11 (36.67%) | |
| PSA, ng/mL | 0.453 | ||
| < 10 | 27 (22.31%) | 5 (16.67%) | |
| [10–20) | 24 (19.83%) | 9 (30.00%) | |
| ≥ 20 | 70 (57.85%) | 16 (53.33%) | |
| Gleason score | 0.034 | ||
| < 7 | 19 (15.70%) | 2 (6.67%) | |
| = 7 | 53 (43.80%) | 8 (26.67%) | |
| > 7 | 49 (40.50%) | 20 (66.67%) | |
| T stage | 0.005 | ||
| T2 | 80 (66.12%) | 11 (36.67%) | |
| T3 | 26 (21.49%) | 9 (30.00%) | |
| T4 | 15 (12.40%) | 10 (33.33%) | |
| N stage | 0.004 | ||
| N0 | 64 (52.89%) | 9 (30.00%) | |
| N1 | 17 (14.05%) | 12 (40.00%) | |
| Nx | 40 (33.06%) | 9 (30.00%) | |
Data were n (%)
PSA prostate-specific antigen